Get the Stockscreener App
95.03
0.05%
-0.01
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $95.03, with a volume of 105.24K.
It is down -0.05% in the last 24 hours and down -2.89% over the past month.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See More
Previous Close:
$95.04
Open:
$94.84
24h Volume:
105.24K
Relative Volume:
0.08
Market Cap:
$11.21B
Revenue:
$2.77B
Net Income/Loss:
$286.61M
P/E Ratio:
40.44
EPS:
2.35
Net Cash Flow:
$524.11M
1W Performance:
-1.18%
1M Performance:
-2.89%
6M Performance:
-23.09%
1Y Performance:
-24.36%
1-Day Range:
$94.06
$95.30
1-Week Range:
$92.62
$104.41
52-Week Range:
$87.70
$129.50
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
95.10 | 12.22B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
482.60 | 180.56B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
203.63 | 147.13B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
569.24 | 45.45B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
119.32 | 34.14B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
196.19 | 33.86B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity, Inc. (NYSE:RVTY) Q2 2025 Earnings Call Transcript - Insider Monkey
Revvity stock price target lowered to $115 by Bernstein on China headwinds - Investing.com Australia
Revvity: Not A Healthy Diagnosis For This Life Science Business (NYSE:RVTY) - Seeking Alpha
Revvity Inc (RVTY) Q2 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ... - Yahoo Finance
Revvity Inc (RVTY) Q2 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ... By GuruFocus - Investing.com Canada
Revvity’s Resilience: Strong Performance and Growth Opportunities Amidst Challenges - TipRanks
Revvity, Inc. Earnings Call: Mixed Sentiment and Strategic Moves - TipRanks
Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook - MSN
U.S. Markets Closed Mixed Monday As Super Micro Computer Led, Revvity Lagged - Barron's
Why Revvity (RVTY) Stock Is Falling Today - MSN
Revvity Q2: Headwinds From China And Customers, Buy On Weakness (NYSE:RVTY) - Seeking Alpha
Revvity targets 2%-4% organic growth for 2025 as China diagnostics faces new policy headwinds - MSN
Revvity stock price target lowered to $100 at Jefferies on China headwinds - Investing.com Australia
Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’ - Stocktwits
Tesla, AMD, SMCI, Nike, Revvity: Stocks Making The Biggest Moves Today By Stocktwits - Investing.com India
Revvity Stock Tumbles After Earnings. What’s Dragging On the Shares. - Barron's
Revvity Stock Dips on Lowered FY25 EPS Guidance Despite Revenue Optimism - GuruFocus
Revvity: Q2 Earnings Snapshot - CTPost
Revvity sinks after slashing its full-year profit outlook - Sherwood News
Revvity (RVTY) Faces China-Driven Headwinds: Is the Selloff a Buying Opportunity or a Warning Signal? - AInvest
Revvity (RVTY) Shares Tumble Amid Market Activity - GuruFocus
Revvity's Q2 2025 Earnings Call: Navigating Contradictions in Revenue Growth, Market Dynamics, and Regulatory Impacts - AInvest
Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More - Investopedia
Revvity's Earnings Beat vs. Stock Sell-Off: A Contrarian Opportunity in Diagnostics? - AInvest
Revvity Slashes Outlook As China Policy Deals Diagnostics Blow - Yahoo Finance
Revvity Plunges 9.8% as China Reimbursement Shifts Trigger Sell-Off—Is This a Buying Opportunity or a Warning Sign? - AInvest
RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View - Barchart.com
Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand - Reuters
Revvity trims 2025 profit forecast on soft demand for diagnostics in China - whbl.com
Revvity (RVTY) Stock Experiences Significant Decline - GuruFocus
Revvity Stock Tumbles After Earnings. What's Dragging on the Shares - 富途牛牛
Earnings Summary: Revvity (RVTY) reports higher Q2 2025 revenues - AlphaStreet
Revvity Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - sg.finance.yahoo.com
Revvity Q2 Revenue Up 4 Percent - AOL.com
Earnings call transcript: Revvity Q2 2025 beats earnings expectations By Investing.com - Investing.com India
Revvity 2025 Q2 Earnings Beats Expectations as Net Income Falls 2.6% - AInvest
Revvity Surpasses Q2 Forecasts with Solid Revenue Growth Across Divisions - MSN
Revvity Lowers 2025 Outlook As China Sales Falter - Finimize
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - 富途牛牛
Revvity Trims 2025 Profit Forecast as China Policy Changes Hit Diagnostics Demand - US News Money
Revvity Stock Tumbles After Earnings. What’s Dragging on the Shares. - MSN
Revvity, Inc. Reports Strong Q2 Earnings, Surpassing Market ExpectationsNews and Statistics - IndexBox
Revvity Q2 Revenue Up 4 Percent - The Motley Fool
Revvity Inc (RVTY) Q2 2025 Earnings: Revenue Surpasses Estimates at $720M, GAAP EPS Falls Short at $0.46 - GuruFocus
S&P 500 Futures Rise in Premarket Trading; Revvity, Albemarle Lag - Barron's
Revvity (RVTY) Reports Strong Second Quarter 2025 Results, Outperforms Expectations - Tokenist
Revvity Announces Financial Results for Q2 2025 - TradingView
Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Revvity Raises 2025 Revenue Guidance - Nasdaq
Revvity Q2 2025 slides: Revenue growth continues amid margin pressure - Investing.com Australia
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):